New market study, "Colombia Pharmaceuticals & Healthcare Report Q1 2014", has been published

From: Fast Market Research, Inc.
Published: Thu Jan 16 2014

We continue to expect steady growth of the Colombian pharmaceutical market over the five years to 2017. Volume demand - from both demographic and epidemiological points of view - will continue to play an important role in the market development. On the down side, increased focus on cost-containment and persistent intellectual property (IP) shortcomings and market barriers will - to a degree -continue to detract from investment by more risk-averse patented drug makers.

Headline Expenditure Projections

* Pharmaceuticals: COP7,588bn (US$4.22bn) in 2012 to COP8,136bn (US$4.34bn) in 2013; +7.2% in local currency terms and +2.9% in US dollar terms. Forecasts broadly unchanged in relation to the previous quarter.
* Healthcare: COP40,230bn (US$22.39bn) in 2012 to COP43,227bn (US$23.08bn) in 2013; +7.4% in local currency terms and +3.1% in US dollar terms. Forecasts broadly unchanged in relation to the previous quarter.

Full Report Details at

Risk/Reward Rating: In our Q114 regional RRR assessment, Colombia moved up from eight to seventh out of 18 markets surveyed in the Americas region. Colombia boasts above-average Rewards and Risks. Although we caution that the country's intellectual property (IP) regime and that its unresolved security situation will continue to represent barriers to multinational involvement, Colombia will continue to be of interest from the longer-term point of view, not least on account of its substantial population numbers.

Key Trends And Developments

* In October 2013, Canadian Cardiome Pharma Corp's subsidiary, Cardiome Development, entered into an agreement with Colombian Biospifar S.A., under which Biospifar will sell and distribute the former's Brinavess (vernakalant intravenous) - indicated for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults - in Colombia on an exclusive basis. Under the terms of the agreement, Biospifar has agreed to specific annual commercial goals, although financial details of the agreement have not been disclosed.

BMI Economic View: We forecast Colombian real GDP to expand by 4.1% in 2013 and 4.3% in 2014, up from 4.0% in 2012. However, ongoing labour disruptions to exports pose downside risks to our medium-term growth outlook. We maintain a favourable long-term growth outlook, as investment into the infrastructure and oil and gas sectors, combined with a strengthening consumer, will drive robust real GDP growth in the coming years.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2014
- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Chile Pharmaceuticals & Healthcare Report Q1 2014
- Russia Pharmaceuticals & Healthcare Report Q1 2014
- Sweden Pharmaceuticals & Healthcare Report Q1 2014
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »